

COVID-19 Vaccine Tracker | BioSpectrum Asia

06 November 2020 | Analysis | By Ankit Kankar | ankit.kankar@mmactiv.com

This tracker shows various COVID-19 vaccine candidates currently in Phase 3 trials. Sources : Milken Institute , RAPS & Public Domains



Information will be updated weekly. If you notice an issue with this data or wish to submit an update, please email *BioSpectrum* at ankit.kankar@mmactiv.com

Updated 06 November to include new information on vaccine candidates from AstraZeneca/Oxford University, Johnson & Johnson, Bharat Biotech/National Institute of Virology, Pfizer/BioNTech, CureVac, Gamaleya Research Institute, Covaxin and Clover/GSK/Dynavax/Xiamen Inovax Biotech/Sanofi.

Candidate	Mechanism	Company	Institution	Trial Phase
Ad5-nCoV	Recombinant vaccine (adenovirus type 5 vector)	CanSino Biologics	Tongji Hospital ; Wuhan, China	Phase 3
AZD1222	Replication-deficient viral vector vaccine (adenovirus from chimpanzees)	AstraZeneca ; IQVIA ; Serum Institute of India	The University of Oxford , the Jenner Institute	Phase 3
CoronaVac	Inactivated vaccine (formalin with alum adjuvant)	Sinovac	Sinovac Research and Development Co., Ltd.	Phase 3
Covaxin	Inactivated vaccine	Bharat Biotech	National Institute of Virology, ICMR	Phase 3
JNJ-78436735 (formerly Ad26.COV2.S)	Non-replicating viral vector	Johnson & Johnson		Phase 3

mRNA-1273	mRNA-based vaccine	<u>Moderna</u>	<u>Kaiser Permanente Washington Health Research Institute</u>	Phase 3
No name announced	Inactivated vaccine	<u>China National Pharmaceutical Group (Sinopharm)</u>	<u>Wuhan Institute of Biological Products</u> Henan Provincial Center for Disease Control and Prevention	Phase 3
NVX-CoV2373	Nanoparticle vaccine	<u>Novavax</u>		Phase 3